Sarissa Capital Management LP Long-Term Concentrated

CIK: 0001577524 · Show all filings

Period: Q3 2017 (← Previous) (Next →)

Filing Date: Nov 14, 2017

Total Value ($000): $323,993 (100.0% shares, 0.0% debt)

Holdings (9)

BIIB BIOGEN INC 37.1%

Value ($000) $120,193 Shares 383,858 Est. Cost $282.94 Unrealized +4.7%

— BIOVERATIV INC 20.5%

Value ($000) $66,486 Shares 1,165,000 Est. Cost $60.17 Unrealized —

— MEDICINES CO 20.0%

Value ($000) $64,894 Shares 1,752,000 Est. Cost $29.63 Unrealized —

INVA INNOVIVA INC 15.7%

Value ($000) $50,841 Shares 3,600,705 Est. Cost $11.10 Unrealized +19.1%

— ACHILLION PHARMACEUTICALS INC 3.0%

Value ($000) $9,594 Shares 2,136,800 Est. Cost $4.49 Unrealized —

— NOVELION THERAPEUTICS INC 2.2%

Value ($000) $7,205 Shares 1,025,000 Est. Cost $8.42 Unrealized —

— APRICUS BIOSCIENCES INC 0.8%

Value ($000) $2,475 Shares 1,447,906 Est. Cost $1.30 Unrealized —

— ADVAXIS INC 0.4%

Value ($000) $1,417 Shares 339,180 Est. Cost $8.09 Unrealized —

ABBV ABBVIE INC. 0.3%

Value ($000) $888 Shares 10,000 Est. Cost $38.85 Unrealized +38.1%

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
BIIB	BIOGEN INC	383,858	$120,193	37.1%	$282.94	+4.7%	COM	09062X103
—	BIOVERATIV INC	1,165,000	$66,486	20.5%	$60.17	—	COM	09075r100
—	MEDICINES CO	1,752,000	$64,894	20.0%	$29.63	—	COM	584688105
INVA	INNOVIVA INC	3,600,705	$50,841	15.7%	$11.10	+19.1%	COM	45781M101
—	ACHILLION PHARMACEUTICALS INC	2,136,800	$9,594	3.0%	$4.49	—	COM	00448Q201
—	NOVELION THERAPEUTICS INC	1,025,000	$7,205	2.2%	$8.42	—	COM NEW	67001K202
—	APRICUS BIOSCIENCES INC	1,447,906	$2,475	0.8%	$1.30	—	COM NEW	03832V307
—	ADVAXIS INC	339,180	$1,417	0.4%	$8.09	—	COM NEW	007624208
ABBV	ABBVIE INC.	10,000	$888	0.3%	$38.85	+38.1%	COM	00287Y109